121 related articles for article (PubMed ID: 21115427)
1. Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions.
Bartlett JM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S86-95. PubMed ID: 21115427
[TBL] [Abstract][Full Text] [Related]
2. Targeting endocrine resistance: is there a role for mTOR inhibition?
Sheri A; Martin LA; Johnston S
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S79-85. PubMed ID: 21115426
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
Maira SM; Furet P; Stauffer F
Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
[TBL] [Abstract][Full Text] [Related]
4. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
Baselga J
Oncologist; 2011; 16 Suppl 1():12-9. PubMed ID: 21278436
[TBL] [Abstract][Full Text] [Related]
5. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
6. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
7. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q; Lui VW; Yeo W
Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Zardavas D; Fumagalli D; Loi S
Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
[TBL] [Abstract][Full Text] [Related]
9. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
Coughlin CM; Johnston DS; Strahs A; Burczynski ME; Bacus S; Hill J; Feingold JM; Zacharchuk C; Berkenblit A
Breast Cancer Res Treat; 2010 Nov; 124(1):1-11. PubMed ID: 20803067
[TBL] [Abstract][Full Text] [Related]
10. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer.
Castaneda CA; Cortes-Funes H; Gomez HL; Ciruelos EM
Cancer Metastasis Rev; 2010 Dec; 29(4):751-9. PubMed ID: 20922461
[TBL] [Abstract][Full Text] [Related]
11. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
Abraham J
Expert Rev Anticancer Ther; 2015 Jan; 15(1):51-68. PubMed ID: 25306975
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
14. The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions.
Malaguti P; Vari S; Cognetti F; Fabi A
Anticancer Res; 2013 Jan; 33(1):21-8. PubMed ID: 23267124
[TBL] [Abstract][Full Text] [Related]
15. [Targeting Ras-PI3K/mTOR pathway and the predictive biomarkers in endometrial cancer].
Oda K
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1084-7. PubMed ID: 21772091
[TBL] [Abstract][Full Text] [Related]
16. Development of LanthaScreen cellular assays for key components within the PI3K/AKT/mTOR pathway.
Carlson CB; Robers MB; Vogel KW; Machleidt T
J Biomol Screen; 2009 Feb; 14(2):121-32. PubMed ID: 19196698
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Generali D; Fox SB; Brizzi MP; Allevi G; Bonardi S; Aguggini S; Milani M; Bersiga A; Campo L; Dionisio R; Vergoni F; Giardini R; Dogliotti L; Bottini A; Harris AL; Berruti A
Clin Cancer Res; 2008 May; 14(9):2673-80. PubMed ID: 18451231
[TBL] [Abstract][Full Text] [Related]
18. The PI3K/AKT Pathway as a Target for Cancer Treatment.
Mayer IA; Arteaga CL
Annu Rev Med; 2016; 67():11-28. PubMed ID: 26473415
[TBL] [Abstract][Full Text] [Related]
19. [mTOR inhibitor].
Muro K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
[TBL] [Abstract][Full Text] [Related]
20. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor.
Van Aller GS; Carson JD; Tang W; Peng H; Zhao L; Copeland RA; Tummino PJ; Luo L
Biochem Biophys Res Commun; 2011 Mar; 406(2):194-9. PubMed ID: 21300025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
